NO313758B1 - Fremgangsmåte for fremstilling av difteritoksin eller CRM- protein - Google Patents
Fremgangsmåte for fremstilling av difteritoksin eller CRM- protein Download PDFInfo
- Publication number
- NO313758B1 NO313758B1 NO19940774A NO940774A NO313758B1 NO 313758 B1 NO313758 B1 NO 313758B1 NO 19940774 A NO19940774 A NO 19940774A NO 940774 A NO940774 A NO 940774A NO 313758 B1 NO313758 B1 NO 313758B1
- Authority
- NO
- Norway
- Prior art keywords
- plasmid
- crmi97
- diphtheria toxin
- protein
- gene
- Prior art date
Links
- 108010053187 Diphtheria Toxin Proteins 0.000 title claims abstract description 50
- 102000016607 Diphtheria Toxin Human genes 0.000 title claims abstract description 41
- 101150044687 crm gene Proteins 0.000 title claims abstract description 32
- 238000000034 method Methods 0.000 title claims abstract description 19
- 230000008569 process Effects 0.000 title claims description 4
- 238000002360 preparation method Methods 0.000 title description 3
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 69
- 239000013612 plasmid Substances 0.000 claims abstract description 54
- 244000005700 microbiome Species 0.000 claims abstract description 7
- 102000004169 proteins and genes Human genes 0.000 claims description 38
- 238000004519 manufacturing process Methods 0.000 claims description 19
- 241000186216 Corynebacterium Species 0.000 claims description 11
- 230000010076 replication Effects 0.000 claims description 10
- 239000003550 marker Substances 0.000 claims description 8
- 238000004520 electroporation Methods 0.000 claims description 6
- 101100298079 African swine fever virus (strain Badajoz 1971 Vero-adapted) pNG2 gene Proteins 0.000 claims description 4
- 230000009466 transformation Effects 0.000 claims description 4
- 108010034055 CRM45 fragment of diphtheria toxin Proteins 0.000 claims description 3
- 206010013023 diphtheria Diseases 0.000 claims description 3
- 239000003053 toxin Substances 0.000 claims description 2
- 231100000765 toxin Toxicity 0.000 claims description 2
- 238000011426 transformation method Methods 0.000 claims 1
- 241000186227 Corynebacterium diphtheriae Species 0.000 abstract description 29
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 abstract description 14
- 229910052742 iron Inorganic materials 0.000 abstract description 7
- 230000001131 transforming effect Effects 0.000 abstract description 2
- 108010071134 CRM197 (non-toxic variant of diphtheria toxin) Proteins 0.000 abstract 3
- 239000013604 expression vector Substances 0.000 abstract 1
- 230000014616 translation Effects 0.000 abstract 1
- 235000018102 proteins Nutrition 0.000 description 32
- 239000000427 antigen Substances 0.000 description 17
- 108091007433 antigens Proteins 0.000 description 17
- 102000036639 antigens Human genes 0.000 description 17
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 15
- 229960005091 chloramphenicol Drugs 0.000 description 14
- 238000010367 cloning Methods 0.000 description 12
- 230000014509 gene expression Effects 0.000 description 10
- 239000002609 medium Substances 0.000 description 10
- 238000003752 polymerase chain reaction Methods 0.000 description 9
- 230000001320 lysogenic effect Effects 0.000 description 8
- 241000700605 Viruses Species 0.000 description 7
- 230000001105 regulatory effect Effects 0.000 description 7
- 231100000033 toxigenic Toxicity 0.000 description 7
- 230000001551 toxigenic effect Effects 0.000 description 7
- 229920001817 Agar Polymers 0.000 description 6
- 108010076504 Protein Sorting Signals Proteins 0.000 description 6
- 239000008272 agar Substances 0.000 description 6
- 230000001580 bacterial effect Effects 0.000 description 6
- 230000003115 biocidal effect Effects 0.000 description 6
- 108020004414 DNA Proteins 0.000 description 5
- 241000588724 Escherichia coli Species 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 239000000499 gel Substances 0.000 description 5
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 4
- 108020004511 Recombinant DNA Proteins 0.000 description 4
- 241000725643 Respiratory syncytial virus Species 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 239000013600 plasmid vector Substances 0.000 description 4
- 229960005486 vaccine Drugs 0.000 description 4
- 102000003886 Glycoproteins Human genes 0.000 description 3
- 108090000288 Glycoproteins Proteins 0.000 description 3
- 241000606768 Haemophilus influenzae Species 0.000 description 3
- 108010052285 Membrane Proteins Proteins 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000004927 fusion Effects 0.000 description 3
- 230000003612 virological effect Effects 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 2
- 241000186226 Corynebacterium glutamicum Species 0.000 description 2
- 241000620209 Escherichia coli DH5[alpha] Species 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 241000725303 Human immunodeficiency virus Species 0.000 description 2
- 241000588655 Moraxella catarrhalis Species 0.000 description 2
- 241000588652 Neisseria gonorrhoeae Species 0.000 description 2
- 241000588650 Neisseria meningitidis Species 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 108091034117 Oligonucleotide Proteins 0.000 description 2
- 241000702670 Rotavirus Species 0.000 description 2
- 241000193998 Streptococcus pneumoniae Species 0.000 description 2
- 241000193996 Streptococcus pyogenes Species 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 239000012620 biological material Substances 0.000 description 2
- 239000012228 culture supernatant Substances 0.000 description 2
- 229960003276 erythromycin Drugs 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
- 229940047650 haemophilus influenzae Drugs 0.000 description 2
- 208000002672 hepatitis B Diseases 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 244000045947 parasite Species 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 229940031000 streptococcus pneumoniae Drugs 0.000 description 2
- 239000013598 vector Substances 0.000 description 2
- ITFICYZHWXDVMU-IPTZIORSSA-N (2S)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-6-amino-2-[[(2S,3S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-1-[(2S)-2-[[(2S,3R)-2-[[(2S,3S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-amino-4-carboxybutanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-hydroxybutanoyl]amino]-3-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]-4-methylpentanoyl]pyrrolidine-2-carbonyl]amino]-3-sulfanylpropanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-3-methylpentanoyl]amino]hexanoyl]amino]-5-oxopentanoyl]amino]-3-phenylpropanoyl]amino]-3-methylpentanoyl]amino]-4-oxobutanoyl]amino]-4-methylsulfanylbutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-oxopentanoyl]amino]pentanedioic acid Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC2=CNC3=CC=CC=C32)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCC(=O)O)C(=O)O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CS)NC(=O)[C@@H]4CCCN4C(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(=O)O)N ITFICYZHWXDVMU-IPTZIORSSA-N 0.000 description 1
- WTLKTXIHIHFSGU-UHFFFAOYSA-N 2-nitrosoguanidine Chemical compound NC(N)=NN=O WTLKTXIHIHFSGU-UHFFFAOYSA-N 0.000 description 1
- 108010068327 4-hydroxyphenylpyruvate dioxygenase Proteins 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 241000228212 Aspergillus Species 0.000 description 1
- 241000223836 Babesia Species 0.000 description 1
- 241000335423 Blastomyces Species 0.000 description 1
- 241000588832 Bordetella pertussis Species 0.000 description 1
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 1
- 201000006082 Chickenpox Diseases 0.000 description 1
- 241000193449 Clostridium tetani Species 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 108010060123 Conjugate Vaccines Proteins 0.000 description 1
- 241000711573 Coronaviridae Species 0.000 description 1
- 241000595586 Coryne Species 0.000 description 1
- 241001337994 Cryptococcus <scale insect> Species 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- 241000223924 Eimeria Species 0.000 description 1
- 241000991587 Enterovirus C Species 0.000 description 1
- 108091006027 G proteins Proteins 0.000 description 1
- 102000030782 GTP binding Human genes 0.000 description 1
- 108091000058 GTP-Binding Proteins 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 208000005176 Hepatitis C Diseases 0.000 description 1
- 241000228402 Histoplasma Species 0.000 description 1
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- 241000588747 Klebsiella pneumoniae Species 0.000 description 1
- 241000222722 Leishmania <genus> Species 0.000 description 1
- 101710085938 Matrix protein Proteins 0.000 description 1
- 241000712079 Measles morbillivirus Species 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 101710127721 Membrane protein Proteins 0.000 description 1
- 208000002430 Multiple chemical sensitivity Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 101710116435 Outer membrane protein Proteins 0.000 description 1
- 241001631646 Papillomaviridae Species 0.000 description 1
- 208000002606 Paramyxoviridae Infections Diseases 0.000 description 1
- 241000224016 Plasmodium Species 0.000 description 1
- 241000233870 Pneumocystis Species 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108020005091 Replication Origin Proteins 0.000 description 1
- 241000710799 Rubella virus Species 0.000 description 1
- 241000242678 Schistosoma Species 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 102400000368 Surface protein Human genes 0.000 description 1
- 208000000389 T-cell leukemia Diseases 0.000 description 1
- 208000028530 T-cell lymphoblastic leukemia/lymphoma Diseases 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 241000223996 Toxoplasma Species 0.000 description 1
- 241000223104 Trypanosoma Species 0.000 description 1
- 206010046980 Varicella Diseases 0.000 description 1
- 241000607626 Vibrio cholerae Species 0.000 description 1
- 241000710772 Yellow fever virus Species 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 239000013566 allergen Substances 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical group 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 201000008680 babesiosis Diseases 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 235000019365 chlortetracycline Nutrition 0.000 description 1
- 239000013599 cloning vector Substances 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 229940031670 conjugate vaccine Drugs 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000000326 densiometry Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 229940045808 haemophilus influenzae type b Drugs 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 208000005252 hepatitis A Diseases 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229930182823 kanamycin A Natural products 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 230000003071 parasitic effect Effects 0.000 description 1
- 201000000317 pneumocystosis Diseases 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000563 toxic property Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 238000002834 transmittance Methods 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 229940118696 vibrio cholerae Drugs 0.000 description 1
- 229940051021 yellow-fever virus Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
- C12N15/77—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora for Corynebacterium; for Brevibacterium
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/34—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Corynebacterium (G)
Landscapes
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US2728393A | 1993-03-05 | 1993-03-05 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO940774D0 NO940774D0 (no) | 1994-03-04 |
| NO940774L NO940774L (no) | 1994-09-06 |
| NO313758B1 true NO313758B1 (no) | 2002-11-25 |
Family
ID=21836767
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO19940774A NO313758B1 (no) | 1993-03-05 | 1994-03-04 | Fremgangsmåte for fremstilling av difteritoksin eller CRM- protein |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US5614382A (de) |
| EP (1) | EP0616034B1 (de) |
| JP (1) | JP4144813B2 (de) |
| KR (1) | KR100316004B1 (de) |
| CN (1) | CN1100757A (de) |
| AT (1) | ATE280235T1 (de) |
| AU (1) | AU686126B2 (de) |
| BR (1) | BR1100634A (de) |
| CA (1) | CA2116914C (de) |
| CZ (1) | CZ39394A3 (de) |
| DE (1) | DE69434079T2 (de) |
| DK (1) | DK0616034T3 (de) |
| ES (1) | ES2231770T3 (de) |
| FI (1) | FI112090B (de) |
| HU (1) | HUT71320A (de) |
| IL (1) | IL108822A (de) |
| NO (1) | NO313758B1 (de) |
| NZ (1) | NZ260027A (de) |
| PT (1) | PT616034E (de) |
| SK (1) | SK24094A3 (de) |
| ZA (1) | ZA941548B (de) |
Families Citing this family (127)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1996032137A2 (en) * | 1995-04-14 | 1996-10-17 | The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Methods of inducing immune tolerance using immunotoxins |
| US7288254B2 (en) | 1995-10-30 | 2007-10-30 | The United States Of America As Represented By The Secretary, Department Of Health And Human Services, Nih | Use of immunotoxins to induce immune tolerance to pancreatic islet transplantation |
| WO1998039363A2 (en) | 1997-03-05 | 1998-09-11 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Immunotoxins and methods of inducing immune tolerance |
| US7517527B2 (en) | 1995-10-30 | 2009-04-14 | The United States Of America As Represented By The Department Of Health And Human Services | Immunotoxin with in vivo T cell suppressant activity and methods of use |
| US7696338B2 (en) | 1995-10-30 | 2010-04-13 | The United States Of America As Represented By The Department Of Health And Human Services | Immunotoxin fusion proteins and means for expression thereof |
| US7125553B1 (en) | 1996-04-15 | 2006-10-24 | The United States of America as represented by the Department of Health and Human Services c/o Centers for Disease Control and Prevention | Methods of inducing immune tolerance using immunotoxins |
| AU736501B2 (en) * | 1997-03-05 | 2001-07-26 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Novel vectors and expression methods for producing mutant proteins |
| US6676943B1 (en) | 1997-04-24 | 2004-01-13 | Regents Of The University Of Minnesota | Human complement C3-degrading protein from Streptococcus pneumoniae |
| CN1086945C (zh) * | 1997-06-03 | 2002-07-03 | 胡章英 | 白喉口服液 |
| GB9923060D0 (en) * | 1999-09-29 | 1999-12-01 | Chiron Spa | Vaccine |
| MX339524B (es) * | 2001-10-11 | 2016-05-30 | Wyeth Corp | Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica. |
| GB0211118D0 (en) * | 2002-05-15 | 2002-06-26 | Polonelli Luciano | Vaccines |
| WO2004011027A1 (en) * | 2002-07-30 | 2004-02-05 | Baxter International Inc. | Chimeric multivalent polysaccharide conjugate vaccines |
| US7785608B2 (en) * | 2002-08-30 | 2010-08-31 | Wyeth Holdings Corporation | Immunogenic compositions for the prevention and treatment of meningococcal disease |
| US7301554B2 (en) * | 2002-09-20 | 2007-11-27 | Ricoh Company, Ltd. | Light scanning device, scanning line adjusting method, scanning line adjusting control method, image forming apparatus, and image forming method |
| JP4696079B2 (ja) | 2003-12-17 | 2011-06-08 | ヤンセン アルツハイマー イミュノセラピー | Ａβ免疫原性ペプチド担体結合物およびそれの製造方法 |
| US20070134762A1 (en) | 2003-12-17 | 2007-06-14 | Arumugham Rasappa G | Immunogenic peptide carrier conjugates and methods of producing same |
| GB0505996D0 (en) | 2005-03-23 | 2005-04-27 | Glaxosmithkline Biolog Sa | Fermentation process |
| US7709001B2 (en) | 2005-04-08 | 2010-05-04 | Wyeth Llc | Multivalent pneumococcal polysaccharide-protein conjugate composition |
| EP2425854A1 (de) | 2005-04-08 | 2012-03-07 | Wyeth LLC | Multivalente Pneumokokken-Polysaccharidproteinkonjugatzusammensetzung |
| TW200806315A (en) * | 2006-04-26 | 2008-02-01 | Wyeth Corp | Novel formulations which stabilize and inhibit precipitation of immunogenic compositions |
| US8808707B1 (en) | 2006-05-08 | 2014-08-19 | Wyeth Llc | Pneumococcal dosing regimen |
| CA2654014A1 (en) | 2006-05-31 | 2007-12-06 | Silvio Buzzi | Pharmaceutical use of protein molecules immunologically correlated to diphtheria toxin |
| AR064642A1 (es) | 2006-12-22 | 2009-04-15 | Wyeth Corp | Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi |
| CN101265288B (zh) * | 2007-03-13 | 2012-03-21 | 齐鲁制药有限公司 | Crm197突变体的纯化方法 |
| MX340830B (es) | 2009-04-30 | 2016-07-26 | Coley Pharm Group Inc | Vacuna neumococica y usos de la misma. |
| CA2766418C (en) | 2009-06-22 | 2016-03-29 | Wyeth Llc | Compositions and methods for preparing staphylococcus aureus serotype 5 and 8 capsular polysaccharide conjugate immunogenic compositions |
| MY169837A (en) | 2009-06-22 | 2019-05-16 | Wyeth Llc | Immunogenic compositions of staphylococcus aureus antigens |
| IT1398927B1 (it) | 2009-06-25 | 2013-03-28 | Consorzio Interuniversitario Per Lo Sviluppo Dei Sistemi A Grande Interfase Csgi | Espressione batterica di un gene artificiale per la produzione di crm197 e derivati. |
| KR20130072201A (ko) | 2010-03-30 | 2013-07-01 | 피페넥스 인크. | 재조합 독소 단백질의 고수준 발현 |
| AU2010201410B2 (en) * | 2010-03-30 | 2015-04-30 | Pelican Technology Holdings, Inc. | High level expression of recombinant CRM197 |
| CN107080838A (zh) | 2010-06-04 | 2017-08-22 | 惠氏有限责任公司 | 疫苗制剂 |
| EP2942061A3 (de) | 2010-06-07 | 2016-01-13 | Pfizer Vaccines LLC | Ige-ch3-peptidimpfstoff |
| CA2808975C (en) | 2010-08-23 | 2018-10-30 | Wyeth Llc | Stable formulations of neisseria meningitidis rlp2086 antigens |
| EP3056212B1 (de) | 2010-09-10 | 2019-04-03 | Wyeth LLC | Non-lipidierten varianten von neisseria meningitidis orf2086 antigene |
| BR112013030963B1 (pt) | 2011-06-01 | 2020-12-01 | Xiamen University | proteína de fusão, polinucleotídio, constructo, vetor, célula hospedeira, composição farmacêutica ou vacina, uso da proteína de fusão, método para modificar uma proteína alvo para melhorar sua imunogenicidade e uso do fragmento de crm197 ou um fragmento do mesmo |
| SA115360586B1 (ar) | 2012-03-09 | 2017-04-12 | فايزر انك | تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها |
| CN107056901B (zh) | 2012-03-09 | 2021-05-07 | 辉瑞公司 | 脑膜炎双球菌组合物及其方法 |
| US9169304B2 (en) | 2012-05-01 | 2015-10-27 | Pfenex Inc. | Process for purifying recombinant Plasmodium falciparum circumsporozoite protein |
| KR102057217B1 (ko) | 2012-06-20 | 2020-01-22 | 에스케이바이오사이언스 주식회사 | 다가 폐렴구균 다당류-단백질 접합체 조성물 |
| CA2879272A1 (en) | 2012-07-16 | 2014-01-23 | Robert G.K. DONALD | Saccharides and uses thereof |
| CN102766647A (zh) * | 2012-07-25 | 2012-11-07 | 天津康希诺生物技术有限公司 | 在白喉杆菌中稳定复制的表达载体及含该载体的白喉杆菌 |
| RU2724840C2 (ru) | 2012-08-16 | 2020-06-25 | Пфайзер Инк. | Способы гликоконъюгирования и композиции |
| US9855324B2 (en) | 2012-10-03 | 2018-01-02 | Glaxosmithkline Biologicals Sa | Immunogenic compositions |
| KR20140075196A (ko) | 2012-12-11 | 2014-06-19 | 에스케이케미칼주식회사 | 다가 폐렴구균 다당류-단백질 접합체 조성물 |
| KR20140075201A (ko) | 2012-12-11 | 2014-06-19 | 에스케이케미칼주식회사 | 다가 폐렴구균 다당류-단백질 접합체 조성물 |
| HUE047120T2 (hu) | 2012-12-20 | 2020-04-28 | Pfizer | Glikokonjugációs eljárás |
| SG11201505301XA (en) | 2013-01-04 | 2015-08-28 | Obi Pharma Inc | Vaccines with higher carbohydrate antigen density and novel saponin adjuvant |
| CA2903716C (en) | 2013-03-08 | 2019-04-09 | Pfizer Inc. | Immunogenic fusion polypeptides |
| US9707153B2 (en) | 2013-04-24 | 2017-07-18 | Corning Incorporated | Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients |
| CN104140972B (zh) * | 2013-05-07 | 2018-01-23 | 上海惠盾生物技术有限公司 | 白喉毒素突变体crm197的制备方法 |
| CN105705467B (zh) | 2013-08-26 | 2019-09-27 | 康宁股份有限公司 | 用于化学强化的玻璃的局部退火的方法 |
| RU2662968C2 (ru) | 2013-09-08 | 2018-07-31 | Пфайзер Инк. | Иммуногенная композиция против neisseria meningitidis (варианты) |
| WO2015095868A1 (en) | 2013-12-20 | 2015-06-25 | Wake Forest University Health Sciences | Methods and compositions for increasing protective antibody levels induced by pneumococcal polysaccharide vaccines |
| NZ755769A (en) | 2014-01-21 | 2023-06-30 | Pfizer | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
| AU2015208822B2 (en) | 2014-01-21 | 2020-06-18 | Pfizer Inc. | Streptococcus pneumoniae capsular polysaccharides and conjugates thereof |
| KR102049826B1 (ko) | 2014-01-21 | 2019-12-03 | 화이자 인코포레이티드 | 스트렙토코쿠스 뉴모니아에 피막 폴리사카라이드 및 그의 접합체 |
| US11160855B2 (en) | 2014-01-21 | 2021-11-02 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
| AU2015210674B2 (en) | 2014-01-31 | 2017-08-24 | Fina Biosolutions, Llc | Expression and purification of CRM197 and related proteins |
| EP3443983B1 (de) | 2014-02-14 | 2022-07-20 | Pfizer Inc. | Immunogene glykoproteinkonjugate |
| US9815886B2 (en) | 2014-10-28 | 2017-11-14 | Adma Biologics, Inc. | Compositions and methods for the treatment of immunodeficiency |
| MX2017006506A (es) | 2014-11-20 | 2018-03-12 | Biological E Ltd | Polinucleotido optimizado en el codon para la expresion de alto nivel de crm197. |
| IL252915B2 (en) | 2015-01-15 | 2024-04-01 | Pfizer | Immunogenic preparations for use in pneumococcal vaccines |
| WO2016132294A1 (en) | 2015-02-19 | 2016-08-25 | Pfizer Inc. | Neisseria meningitidis compositions and methods thereof |
| KR102045663B1 (ko) | 2015-05-04 | 2019-11-15 | 화이자 인코포레이티드 | B군 스트렙토코쿠스 폴리사카라이드-단백질 접합체, 접합체를 생산하는 방법, 접합체를 포함하는 면역원성 조성물, 및 그의 용도 |
| PL3313436T3 (pl) | 2015-06-23 | 2021-06-14 | Biological E Limited | Wielowartościowa skoniugowana szczepionka przeciw pneumokokom |
| TWI756893B (zh) | 2015-07-21 | 2022-03-01 | 美商輝瑞股份有限公司 | 包含經共軛之莢膜糖抗原的致免疫性組成物、包含該致免疫性組成物之套組及彼等之用途 |
| JP6884145B2 (ja) | 2015-11-20 | 2021-06-09 | ファイザー・インク | 肺炎連鎖球菌ワクチンにおいて用いるための免疫原性組成物 |
| CA3017143A1 (en) | 2016-03-10 | 2017-09-14 | The Johns Hopkins University | Methods of producing aggregate-free monomeric diphtheria toxin fusion proteins and therapeutic uses |
| US11965009B2 (en) | 2016-03-10 | 2024-04-23 | The Johns Hopkins University | Methods of producing aggregate-free monomeric diphtheria toxin fusion proteins and therapeutic uses |
| US11203626B2 (en) | 2016-03-10 | 2021-12-21 | The Johns Hopkins University | Methods of producing aggregate-free monomeric diphtheria toxin fusion proteins and therapeutic uses |
| EP3269385A1 (de) | 2016-07-12 | 2018-01-17 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Pneumokokken-polysaccharid-proteinkonjugatzusammensetzung |
| US11191822B2 (en) | 2016-06-22 | 2021-12-07 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Pneumococcal polysaccharide-protein conjugate composition |
| CN109862908B (zh) | 2016-08-05 | 2023-05-02 | 圣诺菲·帕斯图尔公司 | 多价肺炎球菌多糖-蛋白质缀合物组合物 |
| WO2018027123A1 (en) | 2016-08-05 | 2018-02-08 | Sanofi Pasteur, Inc. | Multivalent pneumococcal polysaccharide-protein conjugate composition |
| BR112019006278A2 (pt) | 2016-09-30 | 2019-07-02 | Biological E Ltd | composições de vacina pneumocócica multivalente que compreendem conjugados de polissacarídeo-proteína |
| US10751402B2 (en) | 2016-11-09 | 2020-08-25 | Pfizer Inc. | Immunogenic compositions and uses thereof |
| US11951165B2 (en) | 2016-12-30 | 2024-04-09 | Vaxcyte, Inc. | Conjugated vaccine carrier proteins |
| EP3562503A2 (de) | 2016-12-30 | 2019-11-06 | Sutrovax, Inc. | Polypeptid-antigen-konjugate mit nichtnatürlichen aminosäuren |
| WO2018134693A1 (en) | 2017-01-20 | 2018-07-26 | Pfizer Inc. | Immunogenic compositions for use in pneumococcal vaccines |
| KR102650073B1 (ko) | 2017-01-31 | 2024-03-20 | 머크 샤프 앤드 돔 엘엘씨 | 스트렙토코커스 뉴모니아 혈청형 19f 유래의 협막 다당류 단백질 접합체의 제조 방법 |
| CN110234658B (zh) | 2017-01-31 | 2024-03-12 | 辉瑞大药厂 | 脑膜炎奈瑟菌组合物及其使用方法 |
| KR101908590B1 (ko) | 2017-02-01 | 2018-10-16 | (주)포바이오코리아 | Crm197의 용해성 단백질 발현 및 정제 방법 |
| WO2018144799A1 (en) | 2017-02-03 | 2018-08-09 | SCHADECK, Eva, Barbara | Haemophilus influenzae saccharide-carrier conjugate compositions and uses thereof |
| US10259865B2 (en) | 2017-03-15 | 2019-04-16 | Adma Biologics, Inc. | Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection |
| JP7161493B2 (ja) * | 2017-04-22 | 2022-10-26 | バイオロジカル イー リミテッド | Ｃｒｍ１９７の高レベル製造のための改良法 |
| CA3074708A1 (en) | 2017-09-07 | 2019-03-14 | Merck Sharp & Dohme Corp. | Pneumococcal polysaccharides and their use in immunogenic polysaccharide-carrier protein conjugates |
| WO2019139692A2 (en) | 2017-12-06 | 2019-07-18 | Merck Sharp & Dohme Corp. | Compositions comprising streptococcus pneumoniae polysaccharide-protein conjugates and methods of use thereof |
| KR102475419B1 (ko) * | 2018-07-16 | 2022-12-07 | 주식회사 유바이오로직스 | Crm197을 고농도로 발현하는 코리네박테리움 균주 |
| US11260119B2 (en) | 2018-08-24 | 2022-03-01 | Pfizer Inc. | Escherichia coli compositions and methods thereof |
| BR112021005425A2 (pt) | 2018-09-23 | 2021-06-15 | Biological E Limited | polissacarídeos capsulares purificados de streptococcus pneumoniae |
| CN109100517A (zh) * | 2018-10-08 | 2018-12-28 | 武汉生命科技股份有限公司 | 一种用于检测白喉抗体的抗原蛋白、试剂盒及制备方法 |
| US20220016229A1 (en) | 2018-12-12 | 2022-01-20 | Pfizer Inc. | Immunogenic Multiple Hetero-Antigen Polysaccharide-Protein Conjugates and uses thereof |
| MX2021007496A (es) | 2018-12-19 | 2021-08-05 | Merck Sharp & Dohme Llc | Composiciones que comprenden conjugados de polisacarido de streptococcus pneumoniae con proteina y sus metodos de uso. |
| JP7239509B6 (ja) | 2019-02-22 | 2023-03-28 | ファイザー・インク | 細菌多糖類を精製するための方法 |
| US20220184199A1 (en) | 2019-04-10 | 2022-06-16 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof |
| CN114728050A (zh) | 2019-07-31 | 2022-07-08 | 圣诺菲·帕斯图尔公司 | 多价肺炎球菌多糖-蛋白质缀合物组合物及其使用方法 |
| CA3159573A1 (en) | 2019-11-01 | 2021-05-06 | Pfizer Inc. | Escherichia coli compositions and methods thereof |
| WO2021165847A1 (en) | 2020-02-21 | 2021-08-26 | Pfizer Inc. | Purification of saccharides |
| IL295632A (en) | 2020-02-23 | 2022-10-01 | Pfizer | Escherichia coli preparations and their methods |
| EP3900739A1 (de) | 2020-04-21 | 2021-10-27 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Synthetische streptococcus-pneumoniae-saccharid-konjugate zum konservierten membranprotein |
| EP3919076A1 (de) | 2020-06-02 | 2021-12-08 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Synthetische oligosaccharidimpfstoffe gegen streptococcus pneumoniae mit mikropartikel-adjuvans-formulierungen |
| WO2022043855A1 (en) | 2020-08-26 | 2022-03-03 | Pfizer Inc. | Group b streptococcus polysaccharide-protein conjugates, methods for producing conjugates, immunogenic compositions comprising conjugates, and uses thereof |
| IL308201A (en) | 2020-09-17 | 2024-01-01 | Janssen Pharmaceuticals Inc | Multivalent vaccine compositions and uses thereof |
| US20230383324A1 (en) | 2020-10-22 | 2023-11-30 | Pfizer Inc. | Methods for purifying bacterial polysaccharides |
| TW202227467A (zh) | 2020-10-27 | 2022-07-16 | 美商輝瑞大藥廠 | 大腸桿菌組合物及其方法 |
| IL302413A (en) | 2020-11-04 | 2023-06-01 | Pfizer | Immunogenic preparations for use in pneumococcal vaccines |
| CA3200968A1 (en) | 2020-11-10 | 2022-05-19 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
| US20220202923A1 (en) | 2020-12-23 | 2022-06-30 | Pfizer Inc. | E. coli fimh mutants and uses thereof |
| KR20220102871A (ko) | 2021-01-14 | 2022-07-21 | (주)셀트리온 | 다가 폐렴구균 다당류-단백질 접합체를 포함하는 면역원성 조성물 |
| TW202245835A (zh) | 2021-02-04 | 2022-12-01 | 美商默沙東有限責任公司 | 用於肺炎球菌結合物疫苗之奈米乳化液佐劑組合物 |
| WO2022234416A1 (en) | 2021-05-03 | 2022-11-10 | Pfizer Inc. | Vaccination against pneumoccocal and covid-19 infections |
| WO2022234405A1 (en) | 2021-05-03 | 2022-11-10 | Pfizer Inc. | Vaccination against bacterial and betacoronavirus infections |
| EP4346893A2 (de) | 2021-05-28 | 2024-04-10 | Pfizer Inc. | Immunogene zusammensetzungen mit konjugierten kapselsaccharidantigenen und verwendungen davon |
| PE20240090A1 (es) | 2021-05-28 | 2024-01-16 | Pfizer | Composiciones inmunogenas que comprenden antigenos de sacarido capsular conjugados y sus usos |
| KR20240128715A (ko) | 2022-01-13 | 2024-08-26 | 화이자 인코포레이티드 | 접합된 피막 사카라이드 항원을 포함하는 면역원성 조성물 및 그의 용도 |
| WO2023161817A1 (en) | 2022-02-25 | 2023-08-31 | Pfizer Inc. | Methods for incorporating azido groups in bacterial capsular polysaccharides |
| WO2023218322A1 (en) | 2022-05-11 | 2023-11-16 | Pfizer Inc. | Process for producing of vaccine formulations with preservatives |
| WO2024084397A1 (en) | 2022-10-19 | 2024-04-25 | Pfizer Inc. | Vaccination against pneumoccocal and covid-19 infections |
| WO2024089001A1 (en) | 2022-10-24 | 2024-05-02 | Idorsia Pharmaceuticals Ltd | Vaccine against klebsiella pneumoniae |
| WO2024110827A1 (en) | 2022-11-21 | 2024-05-30 | Pfizer Inc. | Methods for preparing conjugated capsular saccharide antigens and uses thereof |
| US20240181028A1 (en) | 2022-11-22 | 2024-06-06 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
| WO2024116096A1 (en) | 2022-12-01 | 2024-06-06 | Pfizer Inc. | Pneumococcal conjugate vaccine formulations |
| WO2024121280A1 (en) | 2022-12-08 | 2024-06-13 | Idorsia Pharmaceuticals Ltd | Vaccine against klebsiella pneumoniae |
| WO2024166008A1 (en) | 2023-02-10 | 2024-08-15 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
| WO2024201324A2 (en) | 2023-03-30 | 2024-10-03 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
| WO2024214016A1 (en) | 2023-04-14 | 2024-10-17 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH660375A5 (it) * | 1983-02-08 | 1987-04-15 | Sclavo Spa | Procedimento per la produzione di proteine correlate alla tossina difterica. |
| FR2549855B1 (fr) * | 1983-07-29 | 1987-03-27 | Grp Genie Genetique | Sequence nucleotidique codant pour le peptide signal de la toxine diphterique, vecteur contenant cette sequence nucleotidique, leur application a la transformation de micro-organismes et compositions peptidiques obtenues |
-
1994
- 1994-02-07 ES ES94101770T patent/ES2231770T3/es not_active Expired - Lifetime
- 1994-02-07 DK DK94101770T patent/DK0616034T3/da active
- 1994-02-07 EP EP94101770A patent/EP0616034B1/de not_active Expired - Lifetime
- 1994-02-07 DE DE69434079T patent/DE69434079T2/de not_active Expired - Lifetime
- 1994-02-07 PT PT94101770T patent/PT616034E/pt unknown
- 1994-02-07 AT AT94101770T patent/ATE280235T1/de not_active IP Right Cessation
- 1994-02-22 CZ CZ94393A patent/CZ39394A3/cs unknown
- 1994-02-28 SK SK240-94A patent/SK24094A3/sk unknown
- 1994-03-01 JP JP05442894A patent/JP4144813B2/ja not_active Expired - Lifetime
- 1994-03-02 IL IL10882294A patent/IL108822A/en not_active IP Right Cessation
- 1994-03-03 CA CA002116914A patent/CA2116914C/en not_active Expired - Lifetime
- 1994-03-04 AU AU57595/94A patent/AU686126B2/en not_active Expired
- 1994-03-04 ZA ZA941548A patent/ZA941548B/xx unknown
- 1994-03-04 FI FI941050A patent/FI112090B/fi not_active IP Right Cessation
- 1994-03-04 NO NO19940774A patent/NO313758B1/no not_active IP Right Cessation
- 1994-03-04 HU HU9400657A patent/HUT71320A/hu unknown
- 1994-03-04 NZ NZ260027A patent/NZ260027A/en not_active IP Right Cessation
- 1994-03-04 KR KR1019940004356A patent/KR100316004B1/ko not_active IP Right Cessation
- 1994-03-04 CN CN94102360A patent/CN1100757A/zh active Pending
-
1995
- 1995-05-25 US US08/450,333 patent/US5614382A/en not_active Expired - Lifetime
-
1997
- 1997-05-13 BR BR1100634-0A patent/BR1100634A/pt active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| EP0616034B1 (de) | 2004-10-20 |
| DK0616034T3 (da) | 2005-02-21 |
| AU5759594A (en) | 1994-09-08 |
| CZ39394A3 (en) | 1995-02-15 |
| ATE280235T1 (de) | 2004-11-15 |
| HU9400657D0 (en) | 1994-05-30 |
| CA2116914C (en) | 2005-02-08 |
| SK24094A3 (en) | 1995-03-08 |
| NZ260027A (en) | 1996-03-26 |
| DE69434079D1 (de) | 2004-11-25 |
| EP0616034A2 (de) | 1994-09-21 |
| FI112090B (fi) | 2003-10-31 |
| ES2231770T3 (es) | 2005-05-16 |
| PT616034E (pt) | 2005-02-28 |
| IL108822A0 (en) | 1994-06-24 |
| HUT71320A (en) | 1995-11-28 |
| CA2116914A1 (en) | 1994-09-06 |
| KR100316004B1 (ko) | 2002-02-19 |
| CN1100757A (zh) | 1995-03-29 |
| DE69434079T2 (de) | 2005-02-24 |
| US5614382A (en) | 1997-03-25 |
| FI941050A0 (fi) | 1994-03-04 |
| EP0616034A3 (en) | 1996-10-16 |
| ZA941548B (en) | 1994-10-03 |
| FI941050A (fi) | 1994-09-06 |
| AU686126B2 (en) | 1998-02-05 |
| NO940774D0 (no) | 1994-03-04 |
| IL108822A (en) | 2004-09-27 |
| JPH06292593A (ja) | 1994-10-21 |
| KR940021731A (ko) | 1994-10-19 |
| JP4144813B2 (ja) | 2008-09-03 |
| NO940774L (no) | 1994-09-06 |
| BR1100634A (pt) | 1999-12-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO313758B1 (no) | Fremgangsmåte for fremstilling av difteritoksin eller CRM- protein | |
| US7355016B2 (en) | Methods for detection of mycobacteria | |
| EP0712442B1 (de) | Rekombinante tetc-fusionsprotein enthaltene impfstoffzusammensetzungen | |
| EP0544685A1 (de) | Mykobakterieller expressionsvektor | |
| NO325016B1 (no) | Fremgangsmate for fremstilling av en proteinanalog til Bordetella-eksotoksin, polypeptidanalog av S1-subenhet fra Bordetella pertussis-toksin og vaksine mot pertussis. | |
| US20100303849A1 (en) | Lipidated Vaccine against Dengue Virus Infection | |
| JP2023154063A (ja) | 肺炎球菌表面タンパク質Ａ（ＰｓｐＡ）の発現 | |
| US8147841B2 (en) | Clostridium toxin, and process for the preparation of immunogenic composition | |
| AU743165B2 (en) | Live attenuated bacteria of the species Actinobacillus pleuropneumoniae | |
| EP0742829B1 (de) | Expression heterologer proteine in abgeschwächten bakterien mittels des htra-promotors | |
| US6033877A (en) | Peptide expression and delivery system | |
| AU2002301780B2 (en) | Clostridium toxin and method for preparing immunogenic compositions | |
| AU2007201975B2 (en) | Clostridium Toxin and Method for Preparing Immunogenic Compositions | |
| CN111808202A (zh) | 产气荚膜梭菌基因工程亚单位疫苗、其制备方法及应用 | |
| EA045199B1 (ru) | ЭКСПРЕССИЯ ПНЕВМОКОККОВОГО ПОВЕРХНОСТНОГО БЕЛКА А (PspA) | |
| NO304188B1 (no) | Nukleotidsekvens som koder for et ytre membranprotein fra Neisseria meningitt |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM1K | Lapsed by not paying the annual fees |